BMS didn’t want to choose between clinical expertise and financial know-how when selecting a new strategy leader. The Big ...

Biotech has always been a little unconventional, but, as the industry’s bear market drags on, efforts to stay afloat are ...

The Alliance for Regenerative Medicine has voiced deep disappointment about reports that the FDA has put the director of its ...

The FDA has stopped new clinical trials that export American citizens’ living cells from the U.S. to “China and other hostile ...

Multiple developers of connected diabetes hardware have announced plans this week to link their insulin pumps with continuous ...

Life sciences investment firm Syncona has blamed the “particularly challenging” market conditions for shifting its strategy ...

The miniaturized surgical robot maker Virtual Incision has pinched a new CEO, as it aims to expand its commercial reach ...

In May, the company announced the failure of the monoclonal antibody birtamimab to improve mortality in a phase 3 trial of ...

All the figurative FDA trains are running on time, according to the agency’s leader Marty Makary, M.D. | “I'm proud to report ...

The FDA is introducing a new priority voucher program designed to shorten the drug review process from 10 to 12 months down ...

The Department of Health and Human Services is allegedly denying clinical trial funding for biotechs based on their ties to ...

Arialys Therapeutics' precision medicine has shown preclinical potential to address the underlying cause of anti-NMDA ...